<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> is one of the commonest <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> in both men and women </plain></SENT>
<SENT sid="1" pm="."><plain>In spite of significant progress in screening and in surgical and therapeutic interventions, <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is still a major public health problem </plain></SENT>
<SENT sid="2" pm="."><plain>Accumulating evidence suggests that targeting inflammatory pathways may provide protection against the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="23899">Eicosanoids</z:chebi> derived from the enzymes cyclooxygenase (COX) and lipoxygenase (LOX) may contribute to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Approaches for targeting COX-1 and COX-2 with traditional <z:chebi fb="0" ids="35475">nonsteroidal anti-inflammatory agents</z:chebi> or targeting COX-2 with specific inhibitors are highly successful at the preclinical and clinical levels; however, large-scale clinical applicability of these agents is limited owing to unwanted side effects </plain></SENT>
<SENT sid="5" pm="."><plain>Emerging studies suggests that 5-LOX-derived <z:chebi fb="0" ids="25029">leukotrienes</z:chebi> may contribute to <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumor</z:e> development and risk of thrombotic events </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, developing drugs that target both 5-LOX and COX-2 may provide a safer strategy </plain></SENT>
<SENT sid="7" pm="."><plain>In this review, we discuss evidence for the involvement of 5-LOX in <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumor</z:e> development and targeting 5-LOX and COX-2 with synthetic and naturally occurring agents for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> prevention </plain></SENT>
</text></document>